Search Results for "Dana Farber Xl147"
Original Source: Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects with solid tumors or lymphoma. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.
Matching Channels
None
Matching News
Dana-Farber study shows newly isolated 'beige fat' cells could help fight obesity
(Dana-Farber Cancer Institute) Scientists at Dana-Farber Cancer Institute have isolated a new type of energy-burning fat cell in adult humans which they say may have therapeutic potential for treating...
Dana-Farber Cancer Institute to support BrainStorm's phase 2 ALS trial
BrainStorm Cell Therapeutics and Dana-Farber Cancer Institute have entered into collaboration, under which Dana-Farber will provide cGMP-compliant clean room facilities for the production of BrainStor...
Dana-Farber Scientists find potential loophole in pancreatic cancer defenses
(Dana-Farber Cancer Institute) Dana-Farber scientists have found that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted...
OMNI Health Media Develops Cancer Social Media Platform for Dana-Farber Cancer Institute
For Immediate Release October 9, 2012 OMNI Health Media Develops Cancer Social Media Platform for Dana-Farber Cancer Institute Dana-Farber helps cancer patients connect and support each other. SUN VAL...
GNS joins forces with Dana-Farber, Mount Sinai to build myeloma computer models
GNS Healthcare has partnered with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to build a computer model of multiple myeloma.
A male contraceptive pill in the making?
(Dana-Farber Cancer Institute) Researchers at Dana-Farber Cancer Institute and Baylor College of Medicine report in the Aug. 17 issue of Cell that they have used a small molecule compound to generate...
New tool determines leukemia cells' 'readiness to die,' may guide clinical care
(Dana-Farber Cancer Institute) Dana-Farber researchers have developed a method for determining how ready acute myeloid leukemia cells are to die, a finding that may enable oncologists to choose more e...
Blood levels of immune protein predict risk in Hodgkin disease
(Dana-Farber Cancer Institute) Dana-Farber researchers found levels galectin-1, an immunity-related protein, could be the basis of a test and potentially a targeted treatment for Hodgkin lymphoma.
Matching PubMed Articles
The optimal management of asparaginase-associated thrombotic complications is not well-defined. We report the features, management and outcome of paediatric (ages 0-18 years) and adult (18-50 year...
Concordance and discordance in tumor genomic profiling.
Despite improvements in treatment and overall survival rates, survivors of lymphoma may have long-term and late effects. Given the immense risk for cardiac disease after treatment for Hodgkin lymphoma...
Renal disease appears not to affect carcinogenesis in CD151-null mice.
